Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AUTO1 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| AUTO1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AUTO1 | BIOLOGICAL | Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells |
INCLUSION CRITERIA: * \< 18 years old at screening * ≥ 6 kg body weight at screening Pediatric patients with r/r B ALL r/r CD19-positive aggressive mature B including the B NHL subtypes: i) diffuse large B cell lymphoma, ii) Burkitt's lymphoma, iii) primary mediastinal large B cell lymphoma, iv) ...
AUTO1 is an investigational CD19-targeted CAR T cell therapy being studied for relapsed or refractory B cell acute lymphoblastic leukemia (ALL). It is also being evaluated in pediatric patients with relapsed or refractory B cell ALL and aggressive mature B-cell non-Hodgkin lymphoma (B NHL). The drug is in Phase 1 clinical development.
AUTO1 targets CD19, a protein found on B cells. As a CD19-targeted CAR T cell therapy, it is designed to recognize and attack CD19-expressing cancer cells in patients with B cell malignancies, including relapsed or refractory B cell acute lymphoblastic leukemia.
AUTO1 is being developed by Autolus Therapeutics plc, a biopharmaceutical company listed on the NASDAQ under the ticker symbol AUTL. The company is conducting clinical trials of AUTO1 in adult and pediatric patients with B cell acute lymphoblastic leukemia and related B cell malignancies.
AUTO1 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. Two Phase 1 trials are currently active, one in adult patients and one in pediatric patients with relapsed or refractory B cell malignancies.
AUTO1 is being studied in two Phase 1 clinical trials. NCT04404660 is an active, not recruiting study in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, with 153 participants. NCT06173518 is a recruiting study in pediatric patients with relapsed or refractory B cell ALL and B cell non-Hodgkin lymphoma, with 30 participants.
Yes, AUTO1 is a CD19-targeted CAR T cell therapy. It is designed to target CD19 on B cells and is being investigated for the treatment of relapsed or refractory B cell acute lymphoblastic leukemia and other B cell malignancies in both adult and pediatric patients.